By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Biomedical this week said that it has consolidated its stock on a 10 for one basis. The Vancouver, BC-based molecular diagnostics company said that the consolidation applies to all of its common shares, stock options, and warrants. Following the consolidation, Response Biomedical has 25,467,200 common shares outstanding.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.